Latest Biotech News

Arrowhead Pharmaceuticals released early Phase 1/2 data indicating its RNAi candidates produced meaningful fat‑loss signals when combined with GLP‑1/GIP receptor agonists in small cohorts. The...

Variant Bio and Boehringer Ingelheim launched a research and licensing collaboration to discover and validate novel targets for kidney and cardiorenal disease, with Variant Bio eligible for...

Pfizer licensed Cartography Biosciences’ ATLAS and SUMMIT platforms to discover tumor‑selective antigens and antigen pairs for an undisclosed cancer indication. Cartography is eligible for up to...

Federal health officials revised the U.S. childhood immunization schedule, narrowing universal recommendations from 17 vaccines to 11, according to a White House‑directed review. Under the change,...

GSK and Ionis announced positive topline results from two Phase 3 registrational trials of bepirovirsen, an antisense oligonucleotide for chronic hepatitis B. The B‑Well 1 and B‑Well 2 studies...

Federal health officials reduced the number of routine childhood vaccine recommendations from 17 to 11 in a policy change announced by HHS and the CDC, a move implemented without the usual ACIP...

Sanofi signed a discovery and licensing agreement with Earendil Labs to use Earendil’s AI‑driven platform to discover bispecific antibodies for autoimmune and inflammatory diseases. The deal...

Amgen agreed to acquire Dark Blue Therapeutics for up to $840 million to add a preclinical targeted protein degrader aimed at MLLT1/3 and other oncology targets. The deal brings Amgen a degrader...

Alumis reported positive topline results from two Phase 3 trials (Onward1 and Onward2) of envudeucitinib, a selective oral TYK2 inhibitor, meeting primary and key secondary endpoints in...

Arrowhead Pharmaceuticals released early clinical data showing its RNAi candidates, including ARO‑INHBE, produced meaningful fat reductions when used with Eli Lilly’s tirzepatide (Zepbound). In...

Eli Lilly expanded its collaboration with Nimbus Therapeutics under a multi‑year, potentially $1.3 billion agreement to develop an oral treatment for obesity and metabolic diseases. The deal...

Insilico Medicine struck an R&D collaboration with Servier valued up to $888 million to discover and develop oncology therapies using Insilico’s AI discovery platforms. The agreement follows...

Natera and Exelixis launched a collaboration for the STELLAR‑316 Phase 3 trial testing zanzalintinib, an oral kinase inhibitor, in MRD‑positive resected stage II/III colorectal cancer. Natera’s...

Moderna submitted regulatory filings in the U.S., EU, Canada and Australia seeking approval for mRNA‑1010, its seasonal mRNA influenza vaccine for people 50 years and older. The company reported...

Federal health officials cut the number of vaccines the Centers for Disease Control and Prevention routinely recommends for children from 17 to 11 following a directive from the White House. The...

Sanofi signed a discovery and development collaboration with AI-driven startup Earendil Labs focused on bispecific antibodies in autoimmune diseases, a deal valued at up to $2.56 billion. Earendil...

Amgen agreed to acquire U.K. oncology startup Dark Blue Therapeutics for up to $840 million to add a preclinical small‑molecule degrader targeting MLLT1/3 and a pipeline of protein degraders aimed...

Alumis reported positive topline results from two Phase 3 trials of envudeucitinib, its selective oral TYK2 inhibitor, meeting primary and key secondary endpoints in moderate‑to‑severe plaque...

GSK and Ionis announced positive topline results from two pivotal Phase 3 studies, B‑Well 1 and B‑Well 2, evaluating bepirovirsen, an antisense oligonucleotide for chronic hepatitis B. The trials...

Eli Lilly expanded its metabolic pipeline with a collaboration and exclusive license from Nimbus Therapeutics to develop an oral obesity treatment, a deal worth up to $1.3 billion with $55 million...